When a BRAF gene mutation activates the downstream MEK->ERK-MAPK signaling pathway and downstream signaling molecules to enhance the expression of proto-oncogenes, it has a certain effect on the development and metastasis of thyroid cancer (9–11). The gene discussed is MAP2K7; the disease is thyroid cancer.